OBSV News and Press, ObsEva SA From 04/22/20

ObsEva SA (NASDAQ: OBSV ) perks up  4%  after hours on the heels of its announcement of the online publication of two abstracts detailing 52-week data on linzagolix in women endometriosis-related pain. The results, first  reported in June 2018, were generated in the Phase 2...

   Significant improvement in quality of life outcomes maintained or increased after 52 weeks of treatment with linzagolix Small, expected, non-clinically relevant increases in serum lipids observed at 12 weeks generally stable at 52 weeks   GENEVA, Switzerland and ...

ObsEva SA (NASDAQ: OBSV ) has nominated  Fabien de Ladonchamps, Vice President Corporate Affairs & Finance, as interim Chief Financial Officer (CFO) and member of the Executive Committee, effective April 10. More news on: ObsEva SA, Healthcare stocks news, Stocks on the move, ...

  Geneva, Switzerland and Boston, MA – April 6, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced the nomination of Fabien de Ladonch...

Geneva, Switzerland and Boston, MA – March 27, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that due to the current situation with COVI...

ObsEva SA (NASDAQ: OBSV ) provides an update on clinical development programs in context of COVID-19 pandemic. More news on: ObsEva SA, Healthcare stocks news, Read more ...

  Patient safety remains the top priority   PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20, as planned   PROLONG trial results expected to be announced in 2H:20, as planned   New patient screening and randomization in EDELWEISS 2 a...

Gainers: Digirad DRAD  +122% . More news on: Tocagen Inc., Menlo Therapeutics Inc., ObsEva SA, Stocks on the move, , Read more ...

  Geneva, Switzerland and Boston, MA – February 27, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release year end 2019 finan...

Geneva, Switzerland and Boston, MA – February 18, 2020  – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that CEO Ernest Loumaye will presen...